Provided by Tiger Trade Technology Pte. Ltd.

AbCellera Biologics

11.67
+0.26002.28%
Post-market: 11.710.0400+0.34%19:13 EDT
Volume:4.54M
Turnover:52.36M
Market Cap:3.78B
PE:-21.39
High:11.73
Open:11.44
Low:11.18
Close:11.41
52wk High:12.58
52wk Low:2.75
Shares:324.00M
Float Shares:221.00M
Volume Ratio:1.14
T/O Rate:2.06%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5455
EPS(LYR):-0.4902
ROE:-17.30%
ROA:-10.39%
PB:4.22
PE(LYR):-23.81

Loading ...

Abcellera Appoints DR. Victor Sandor to Its Board of Directors

THOMSON REUTERS
·
Jun 05

Is AbCellera (ABCL) Turning Upgraded Earnings Forecasts Into a Durable Clinical-Stage Business Model?

Simply Wall St.
·
Jun 04

A Look At AbCellera Biologics (ABCL) Valuation After Improved Earnings Outlook And Sector Outperformance

Simply Wall St.
·
Jun 02

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Hims & Hers Health (HIMS), AbCellera Biologics (ABCL) and Indivior (INDV)

TIPRANKS
·
May 22

AbCellera publishes corporate overview on internal antibody pipeline, platform expansion strategy

Reuters
·
May 20

AbCellera director John S. Montalbano acquires 20,000 common shares for $95,400

Reuters
·
May 19

AbCellera Biologics (ABCL) Q4 Revenue Surge Tests High 20.1x P/S Growth Narrative

Simply Wall St.
·
May 13

AbCellera Biologics Bets Big on 2026 Trial Catalysts

TIPRANKS
·
May 13

Stock Track | AbCellera Biologics Plummets 11.65% Intraday Amid Concerns Over Continued Losses and Rising R&D Expenses Despite Q1 Beat

Stock Track
·
May 12

Analysts’ Opinions Are Mixed on These Healthcare Stocks: West Pharmaceutical Services (WST), CVRx (CVRX) and AbCellera Biologics (ABCL)

TIPRANKS
·
May 12

Stock Track | AbCellera Biologics Plunges 5.47% in Pre-Market Amid Concerns Over Continued Losses and Rising R&D Expenses Despite Q1 Beat

Stock Track
·
May 12

Analysts Offer Insights on Healthcare Companies: Ceribell, Inc. (CBLL) and AbCellera Biologics (ABCL)

TIPRANKS
·
May 12

Stock Track | AbCellera Biologics Plunges 7.24% Post-Market Despite Q1 Beat as Investors Focus on Continued Losses and Rising R&D Expenses

Stock Track
·
May 12

AbCellera Biologics options imply 9.7% move in share price post-earnings

TIPRANKS
·
May 12

Stock Track | AbCellera Biologics Plunges 6.48% After-Hours Despite Beating Q1 Estimates

Stock Track
·
May 12

Stock Track | AbCellera Biologics Soars 7.62% After-Hours on Earnings Beat and Positive Clinical Data

Stock Track
·
May 12

Earnings Flash (ABCL) AbCellera Biologics Posts Q1 Per Share Loss of $0.14, vs. FactSet Est Loss $0.17

MT Newswires Live
·
May 12

AbCellera Biologics Q1 Loss Narrows, Revenue Rises

MT Newswires Live
·
May 12

Abcellera Biologics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 12

AbCellera Q1 revenue more than doubles, beats estimates

Reuters
·
May 12